LONGEVA.

NAD+: adverse events during infusions

In Grant and colleagues’ 2019 pilot, eight men received intravenous NAD+ and three received saline. No adverse events were observed during the six-hour infusions. [1]

Reyna and colleagues’ 2026 retrospective study describes different conditions: four days of infusions in a commercial setting. NAD+ recipients reported moderate or severe gastrointestinal symptoms, increased heart rate and chest pressure, resolving after infusion. [2]

Different conditions and small samples prevent generalizing reaction frequencies or establishing safety of a particular reagent batch or other routes. [1,2]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events during six-hour infusionsEight men received intravenous NAD+, three received saline (pilot study)None observed; the small sample and different conditions do not generalize reaction frequencies[1]
Moderate or severe gastrointestinal symptomsFour days of NAD+ infusions in a commercial setting (retrospective study)Reported; resolved after infusion; no percentage given[2]
Increased heart rateThe same settingReported; resolved after infusion; no frequency given[2]
Chest pressureThe same settingReported; resolved after infusion; no frequency given[2]

References

  1. Grant R et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ https://doi.org/10.3389/fnagi.2019.00257.
  2. Reyna K et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting https://doi.org/10.3389/fragi.2026.1652582.